Skip to content
Checking whether you are signed in

Moderna, Inc.

MRNANasdaqFull coverage

Price
Loading your watchlists

AI-generatedPublished Nov 10, 2026, 8:35 PM UTC

Q3 fiscal 2026 edition

A free account unlocks one dossier edition a month.

Create a free account

Already have an account? Sign in

Summary

Free to read

Moderna sells mRNA vaccines against COVID-19, RSV and flu to US wholesalers and pharmacies and to governments abroad, and shares with Merck an individualised cancer therapy, intismeran, that met its Phase 3 goals in melanoma in 2026. Third-quarter 2026 revenue rose 29% to $1.3 billion, all of the growth from multi-year contracts with the UK, Canada and Australia, while US sales were flat and costs fell by about a fifth. The raised 2026 outlook implies a much weaker fourth quarter, and free cash flow over the last twelve months was minus $1.97 billion. Moatsight estimates revenue of about $2.47 billion over the next four quarters and free cash flow of about minus $1.36 billion, so how large intismeran becomes is what decides the company's future.

In the full dossier

  1. Part 1In brief
  2. Part 2Business explainer
  3. Part 3Earnings
  4. Part 4Valuation and projections
  5. Part 5What changed

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers